In July, Biocon had secured regulatory approval from the European Medicines Agency (EMA) for this new drug product fill-finish line.

The announcement was made before market hours today, 25 September 2026.

Biocon is a Bengaluru-based biopharmaceutical company focused on biosimilars and generic medicines, with operations across more than 120 countries.

The company had reported 355% jump in consolidated net profit to Rs 141 crore in Q1 FY27 from Rs 31 crore in Q1 FY26. Revenue from operations rose by 10% year-on-year (YoY) to Rs 4,336 crore during the period under review.

The scrip shed 0.58% to currently trade at Rs 384.75 on the BSE.